PharmaCorp Rx Inc. PCRX.V
TSX
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | 5.58M | 5.24M | 5.52M | 3.49M | 3.18M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 5.58M | 5.24M | 5.52M | 3.49M | 3.18M |
| Cost of Revenue | 3.33M | 3.20M | 3.39M | 2.06M | 1.91M |
| Gross Profit | 2.25M | 2.04M | 2.13M | 1.42M | 1.26M |
| SG&A Expenses | 2.10M | 1.82M | 2.34M | 1.62M | 1.37M |
| Depreciation & Amortization | 241.10K | 256.90K | 245.20K | 161.40K | 136.30K |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 5.67M | 5.28M | 5.97M | 3.85M | 3.42M |
| Operating Income | -86.40K | -37.40K | -456.50K | -362.20K | -239.00K |
| Income Before Tax | 63.90K | 86.40K | -388.80K | -310.80K | -164.60K |
| Income Tax Expenses | -23.70K | -6.20K | 243.50K | -13.70K | 114.20K |
| Earnings from Continuing Operations | 87.60K | 92.50K | -632.30K | -297.10K | -278.80K |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -65.70K | -13.70K | -21.70K | -13.30K | 1.20K |
| Net Income | 21.90K | 78.90K | -654.00K | -310.40K | -277.60K |
| EBIT | -86.40K | -37.40K | -456.50K | -362.20K | -239.00K |
| EBITDA | 127.40K | 187.20K | -245.00K | -219.20K | -102.70K |
| EPS Basic | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Normalized Basic EPS | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| EPS Diluted | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Normalized Diluted EPS | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Average Basic Shares Outstanding | 174.08M | 174.08M | 148.67M | 117.30M | 117.30M |
| Average Diluted Shares Outstanding | 183.30M | 183.42M | 148.67M | 117.30M | 117.30M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |